BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) occur sporadically, after prior radiation therapy (RT), or in association with neurofibromatosis type 1 (NF1). It is controversial whether patients with NF1-associated MPNST have worse outcomes. We investigated the prognostic significance of sporadic, NF1-associated, and RT-induced MPNST. METHODS: Patients with primary high-grade MPNST from 1982 to 2011 were identified from a prospectively maintained database. Patients with sporadic MPNST were included only if the MPNST was not associated with NF1 or a neurofibroma or if it was immunohistochemically S100-positive. RESULTS: We studied 105 patients; 42 had NF1-associated tumors, 49 sporadic, and 14 RT-induced. Median age at diagnosis was 38 years. Median follow-up for surviving patients was 4 years. Mean tumor diameter was 5.5 cm for RT-induced tumors and 9.7 cm for NF1-associated and sporadic tumors (P=0.004). In multivariate analysis, factors associated with worse disease-specific survival (DSS) were larger size (HR 1.08; 95% CI 1.04-1.13; P<0.001) and positive margin (HR 3.30; 95% CI 1.74-6.28; P<0.001). Age, gender, site of disease, and S100 staining were not associated with DSS. The 3-year and median DSS were similar for NF1 and sporadic cases; combined 3-year DSS was 64% and median DSS was 8.0 years. For RT-induced tumors, 3-year DSS was 49% and median DSS was 2.4 years. The relationship between RT association and DSS approached statistical significance (HR 2.29; 95% CI 0.93-5.67; P=0.072). CONCLUSIONS: Margin status and size remain the most important predictors of DSS in patients with MPNST. NF1-associated and sporadic MPNSTs may be associated with improved DSS compared with RT-induced tumors.
BACKGROUND:Malignant peripheral nerve sheath tumors (MPNSTs) occur sporadically, after prior radiation therapy (RT), or in association with neurofibromatosis type 1 (NF1). It is controversial whether patients with NF1-associated MPNST have worse outcomes. We investigated the prognostic significance of sporadic, NF1-associated, and RT-induced MPNST. METHODS:Patients with primary high-grade MPNST from 1982 to 2011 were identified from a prospectively maintained database. Patients with sporadic MPNST were included only if the MPNST was not associated with NF1 or a neurofibroma or if it was immunohistochemically S100-positive. RESULTS: We studied 105 patients; 42 had NF1-associated tumors, 49 sporadic, and 14 RT-induced. Median age at diagnosis was 38 years. Median follow-up for surviving patients was 4 years. Mean tumor diameter was 5.5 cm for RT-induced tumors and 9.7 cm for NF1-associated and sporadic tumors (P=0.004). In multivariate analysis, factors associated with worse disease-specific survival (DSS) were larger size (HR 1.08; 95% CI 1.04-1.13; P<0.001) and positive margin (HR 3.30; 95% CI 1.74-6.28; P<0.001). Age, gender, site of disease, and S100 staining were not associated with DSS. The 3-year and median DSS were similar for NF1 and sporadic cases; combined 3-year DSS was 64% and median DSS was 8.0 years. For RT-induced tumors, 3-year DSS was 49% and median DSS was 2.4 years. The relationship between RT association and DSS approached statistical significance (HR 2.29; 95% CI 0.93-5.67; P=0.072). CONCLUSIONS: Margin status and size remain the most important predictors of DSS in patients with MPNST. NF1-associated and sporadic MPNSTs may be associated with improved DSS compared with RT-induced tumors.
Authors: Soha Riad; David Biau; Ginger E Holt; Joel Werier; Robert E Turcotte; Peter C Ferguson; Anthony M Griffin; Colleen I Dickie; Peter W Chung; Charles N Catton; Brian O'sullivan; Jay S Wunder Journal: Cancer Date: 2011-10-11 Impact factor: 6.860
Authors: Matteo Anghileri; Rosalba Miceli; Marco Fiore; Luigi Mariani; Andrea Ferrari; Chiara Mussi; Laura Lozza; Paola Collini; Patrizia Olmi; Paolo G Casali; Silvana Pilotti; Alessandro Gronchi Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: Stephen R Grobmyer; John D Reith; Amir Shahlaee; Charles H Bush; Steven N Hochwald Journal: J Surg Oncol Date: 2008-03-15 Impact factor: 3.454
Authors: Changye Zou; Kerrington D Smith; Jun Liu; Guy Lahat; Sarah Myers; Wei-Lien Wang; Wei Zhang; Ian E McCutcheon; John M Slopis; Alexander J Lazar; Raphael E Pollock; Dina Lev Journal: Ann Surg Date: 2009-06 Impact factor: 12.969
Authors: J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren Journal: J Neuroradiol Date: 2018-06-27 Impact factor: 3.447
Authors: Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry Journal: Hum Pathol Date: 2017-05-24 Impact factor: 3.466
Authors: Kelsey L Watson; Ghadah A Al Sannaa; Christine M Kivlin; Davis R Ingram; Sharon M Landers; Christina L Roland; Janice N Cormier; Kelly K Hunt; Barry W Feig; B Ashleigh Guadagnolo; Andrew J Bishop; Wei-Lien Wang; John M Slopis; Ian E McCutcheon; Alexandar J Lazar; Keila E Torres Journal: J Neurosurg Date: 2016-04-01 Impact factor: 5.115
Authors: Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki Journal: Oncologist Date: 2014-01-27
Authors: Andrew J Bishop; Gunar K Zagars; Keila E Torres; Justin E Bird; Barry W Feig; B Ashleigh Guadagnolo Journal: Am J Clin Oncol Date: 2018-05 Impact factor: 2.339